On 13 July, we are hosting the Cancer Tech Accelerator Demo Day where companies from the current cohort present before investors, researchers and medical experts. You’ll hear from the seven finalists teams, selected to receive £70,000 in grant funding to progress their research by Cancer Research UK, Roche UK, and the Medical Research Council. What’s more, you’ll also hear from four Rising Stars who made the cut due to their outstanding potential. Read on for a preview of the companies you can look forward to seeing present, and save your place by registering here

 

Co-founded by Dr Zhengchu Tan and Manoj Murali of Imperial College London, Organa is developing hyper-realistic organ mimics to train the next generation of surgeons and medical robots. As it stands, surgical trainees have faced a five-fold decrease in the number of hands-on surgical training hours, making it increasingly difficult for them to master advanced surgical skills without endangering patients. Similarly, surgical robots require a huge amount of training data to work effectively, which is currently gathered from cadavers and animals. Organa believes their high-fidelity tactile organ mimics will play a critical role in training the next generation of surgeons and surgical robots – and we agree.

 

Elaitra is working on state-of-the-art neural networks to detect breast cancer, a leading cause of mortality among women and among the most common cancers in the US and UK. While widespread X-ray screening helps, it is hampered by a worldwide shortage of radiologists which is why the team developed the technology ViewFinder: a GPS for 3D medical images, which improves the quality of breast cancer detection, and relieves the current bottleneck in diagnosis.. Another exciting company in the cancer-detection space is Cansor, who are developing a new and more accurate test for early, cost-effective detection of prostate cancer which relies on cell-free DNA (cfDNA), the tiny fragments of DNA from different tissues in the body which can be found floating in the blood. At present, prostate cancer detection relies on a prostate specific antigen test which is none too accurate – leading to missed cases and many thousands of preventable deaths. 

 

Working on a different level of abstraction, Turing Biosystems, in collaboration with Newcastle University, aims to harness the power of hybrid AI for precision medicine with a platform that manages and analyses the complexity of biological systems by bringing together multiple layers of patient, clinical, and biological data. The company’s first target is immuno-oncology, where they have developed a unique clinical trial analysis on immune checkpoint inhibitors drawing on multi-omics and clinical metadata. The outcome? An AI platform capable of relating clinical or biological data from different sources to discover novel insights and recommend personalised interventions and treatments unique to the patient.

These are just a few of the startups you can look forward to hearing from at our Cancer Tech Accelerator Demo Day. Click here to see who else is pitching – they are every bit as impressive. Don’t forget to register and we’ll see you there on 13 July.